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Abstract 
Background: The coronavirus disease 2019 (COVID-19) pandemic has spread throughout more than 160 countries, 
infecting millions of people worldwide. To address this health emergency, countries have organized the flow of 
production and innovation to reduce the impact on health. This article shows the response of the Brazilian scientific 
community to meet the urgent needs of the public unified health system [SUS], aiming to guarantee universal access 
to an estimated population of 211 million. By December 2020, Brazil had recorded more than six million cases and 
approximately 175,000 deaths.
Methods: We collected data on research, development and innovation projects carried out by 114 public universi-
ties (plus Oswaldo Cruz Foundation [Fiocruz] and Butantan Institute), as reported on their websites. Additionally, we 
examined the studies on COVID-19 approved by the National Comission for Research Ethics, as well as those reported 
on the Ministry of Education website as of May 15, 2020.
Results: The 789 identified projects were classified according to research categories as follows: development and 
innovation (n = 280), other types of projects (n = 226), epidemiologic research (n = 211), and basic research on disease 
mechanisms (n = 72). Most proposals focused on the development and innovation of personal protective equip-
ment, medical devices, diagnostic tests, medicines and vaccines, which were rapidly identified as research priorities 
by the scientific community. Some promising results have been observed from phase III vaccine trials, one of which is 
conducted in partnership with Oxford University and another of which is performed with Sinovac Biotech. Both trials 
involve thousands of volunteers in their Brazilian arms and include technology transfer agreements with Fiocruz and 
the Butantan Institute, respectively. These vaccines proved to be safe and effective and were immediately licensed for 
emergency use. The provision of doses for the public health system, and vaccination, started on January 17, 2021.
Conclusions: The mobilized Brazilian scientific community has generated comprehensive research, development 
and innovation proposals to meet the most urgent needs. It is important to emphasize that this response was only 
possible due to decades of investment in research, development and innovation in Brazil. We need to reinforce and 
protect the Brazilian science, technology and innovation system from austerity policies that disregard health and 
knowledge as crucial investments for Brazilian society, in line with the constitutional right of universal health access 
and universal health coverage.
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Background
The coronavirus disease 2019 (COVID-19) pandemic 
has forced health authorities around the world to pro-
pose social distancing and other measures, mainly due to 
the ease of transmission and dissemination of the virus 
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through the air [1]. In addition to personal protective 
equipment (PPE) for populations and health profession-
als, products such as mechanical respirators have become 
essential to combat the deadly impact of the pandemic. 
The disease has spread to more than 160 countries, 
infecting millions of people globally. Estimates of severe 
cases have been the main concern of health authorities 
worldwide [2].
This global health emergency has demanded urgent 
responses to lessen the impact of the pandemic, forcing 
the international scientific community to develop and 
improve interventions that can assist public policies in 
slowing the spread of the pandemic in their communi-
ties. In Brazil, the research, development and innovation 
(RD&I) sectors have suffered severe budget cuts since 
2018 [3]. Recently, government officials have denied sci-
entific findings by saying “So what!” as described in The 
Lancet editorial, “COVID-19 in Brazil: So What?” [4]. 
However, universities and public research centers have 
remained focused on their social responsibility and have 
continued to work diligently to help control and mitigate 
the COVID-19 pandemic, using a voluntary work force 
and the existing research infrastructure in a clear demon-
stration of strong institutional resilience.
On February 26, 2020, the first case of COVID-19 was 
identified in Brazil. By May 15, when we conducted this 
survey, 218,000 confirmed cases and 14,000 deaths due to 
COVID-19 had been reported. These figures had jumped 
to six million cases and 175,000 deaths by December 
2020; with regard to the number of cases and deaths, Bra-
zil ranks third internationally. This illustrates the chal-
lenge facing our public Unified Health System (SUS) in 
providing universal access to care and universal health 
coverage, as recommended by the Pan American Health 
Organization (PAHO) [5] and guaranteed by the Brazil-
ian Constitution, to an estimated population of 211 mil-
lion in a country with a vast territory and wide regional 
and social inequalities [6].
Given this context, this article investigates how the 
Brazilian scientific community responded during the 
very early stages of the COVID-19 epidemic.
The research and development (R&D) scenario in Brazil
The Brazilian science and technology (S&T) system is 
composed of public universities and public research 
centers; this helps to explain how health research has 
developed in Brazil over time. Research in the area of 
COVID-19 shows that even with the scarcity of funding, 
universities and public research centers support national 
scientific development.
In Brazil, scientific research in the field of public health 
in the early twentieth century encouraged the develop-
ment of the national health research systems [7], starting 
with the creation of public research centers such as the 
Oswaldo Cruz Foundation (Fiocruz) in Rio de Janeiro 
in 1900 and the Butantan Institute in São Paulo in 1901. 
The creation of the Brazilian Academy of Sciences (ABC) 
followed shortly thereafter, in 1916. The history of Bra-
zil’s health research system is intertwined with the crea-
tion of a network of publicly funded universities. The 
first public university was Amazonas Federal University, 
founded in 1909, followed by substantial federal gov-
ernment investments that led to the creation of 36 uni-
versities by 1974. After three decades of stagnation and 
deterioration (1975–2004), investments in higher educa-
tion accelerated substantially under Presidents Lula and 
Dilma (2003–2016). They launched the “Restructuring 
and Expansion of Federal Universities Project,” REUNI 
(2003–2012), which created 15 new universities, in addi-
tion to refurbishing installations, infusing the faculty 
with qualified researchers, increasing available spaces for 
students in undergraduate courses, expanding the avail-
ability of evening courses and promoting pedagogical 
innovations, all with the aim of reducing social inequali-
ties in the country [8]. In fact, 23% of the existing federal 
universities started during this period, resulting in an 
unprecedented democratization of access to high-level 
education. At present, this network of public universities 
encompasses 68 highly qualified and autonomous univer-
sities that are completely free (unlike universities in the 
United States and European countries) and offer scholar-
ships (tax-free) for undergraduate and graduate (masters, 
doctoral) students as well as postdocs. In addition, there 
are 41 public universities maintained by state govern-
ments and five financed by municipal governments. This 
network of 114 institutions [9] is undoubtedly an impor-
tant and integral part of the scientific and cultural herit-
age of the nation [10].
The implementation of the national science and tech-
nology policy started in 1951, with the creation of the 
National Council for Scientific and Technological Devel-
opment (CNPq) and the Coordination for the Improve-
ment of Higher Education Personnel (CAPES), which 
contributed to transforming universities and public 
research centers into vectors for RD&I. From 2004 to 
2014, the coordinated efforts of the Ministry of Health’s 
Department of Science and Technology (DECIT), CNPq 
and CAPES encouraged the establishment of a health sci-
ence, technology and innovation policy [11]. In addition, 
an agenda of health research priorities was generated and 
implemented, with 3586 projects financed [12]. Starting 
in 2004, federal RD&I investments were also on the rise. 
A recent report from the Brazilian Institute of Applied 
Economic Research (IPEA) analyzed RD&I expendi-
tures from 2000 to 2020. Prior to 2004, the expenditures 
amounted to approximately R$4 million per year. This 
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amount increased steadily, reaching R$13 million in 
2015, but afterwards sharp reductions occurred, and by 
2018 the budget had been reduced to R$5.1 million [3].
Brazil ranked 13th in international scientific publica-
tions in 2015 [11]. The development of the public uni-
versity research infrastructure, as mentioned before, 
together with federal RD&I investments from 2004 to 
2015 were decisive factors facilitating the achievement of 
this rank [3].
Development, innovation and the health 
economic‑industrial complex in Brazil
Because of the COVID-19 public health emergency, soci-
eties in virtually all countries had to organize their flow 
of production and innovation in the hope of reducing the 
impact on the health systems and guaranteeing adequate 
health care for the population. The RD&I sectors in each 
country have assumed the immense responsibility of gen-
erating the domestic responses to reduce the impacts on 
the healthcare and economic systems of their regions 
because, given the magnitude of this pandemic, imports 
of healthcare products and supplies are limited by the 
scarcity of products on the international market. Those 
countries with established health production systems 
(that involve different production chains) are more likely 
to avoid shortages of raw materials and finished products 
that are essential for combatting the pandemic.
However, in Brazil, the knowledge generated by ongo-
ing research that led to Brazil ranking 13th in terms 
of scientific publications did not lead to proportional 
advances in the development of organizational processes 
and technologies. This could explain why, in 2016, Brazil 
ranked 69th on the Global Innovation Index. During the 
pandemic, Brazilian universities struggled to overcome 
the wide disparity between the high level of production 
of scientific knowledge and the low level of scientific 
innovation. In the “ecosystem” of economic and social 
development in which the production sector and govern-
ment participate, the university sector must play a fun-
damental role in transforming knowledge into solutions 
that confer benefits to society [13].
From 2004 to 2015, a concerted effort was made in 
Brazil to stimulate the triple helix model of innova-
tion, which describes the interactions among universi-
ties, industries and governments [14]. Such interactions 
are considered key to innovation in increasingly knowl-
edge-based societies, such as China, as well as in other 
developing countries [15]. The paradigm known as the 
Brazilian health economic-industrial complex (HEIC) 
considers the health sector to be part of the production 
and innovation system that generates wealth and jobs; 
this concept was present in the advancement of SUS in 
recent decades, during which it operated in accordance 
with the market. The rationale that guided the public pol-
icies resulting from this paradigm emphasized the sys-
temic approach and the use of states’ purchasing power 
to push sectorial development [16]. From this point 
of view, the health sector is part of the developmental 
agenda and supports innovation and economic develop-
ment through health industrial complexes [17].
Given this context, this article investigates how the Bra-
zilian scientific community has responded to the threat 
of COVID-19. The knowledge accrued by universities, 
institutes and public health research centers was chal-
lenged by the COVID-19 pandemic, and the scientific 
sector responded immediately by producing health solu-
tions to mitigate the destructive progress of the ongoing 
pandemic. We intend to show the immediate response 
and commitment of the Brazilian scientific community. 
Most of these actions were taken as the result of the sci-
entists’ own initiative and desire to meet the most urgent 
needs of the population affected by COVID-19, and not 
in response to specific calls for proposals.
Methods
To analyze the actions taken by Brazilian scientists to 
meet the needs arising from the COVID-19 pandemic, 
we collected official RD&I projects carried out by 114 
Brazilian public universities (plus Fiocruz and Butantan), 
as reported on their institutional websites (access May 
10–15, 2020). Additionally, we examined all the studies 
on COVID-19 that had been submitted to and approved 
by the National Comission for Research Ethics (CONEP) 
as of May 15, 2020 [18]. Third, we analyzed all the RD&I 
proposals available on the Ministry of Education official 
website on May 15, 2020, which were obtained with web-
scraping computational tools.
We then analyzed and classified the projects into cat-
egories according to information obtained from the pro-
posals’ titles and/or summaries. The following categories 
emerged:
Basic research on disease mechanisms: genetic 
sequencing, viral mutations, physiopathology, immuno-
logical profiles and clinical manifestations of COVID-19.
Epidemiologic research: distribution and evolution of 
the disease, risk factors for COVID-19.
Development and innovation (D&I), organized into 
five subcategories: (a) personal protective equipment 
(PPE): face shields, masks, disinfection mechanisms; (b) 
medical devices: respirators, ventilators, mobile ICUs; (c) 
diagnostic tests: novel tests, rapid tests, alternative body 
fluid samples, test accuracy; (d) vaccines: development of 
vaccines against severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2); (e) medications and therapy: 
drugs, novel treatments for COVID-19.
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Other types of projects: research relevant to COVID-19 
and its social, psychological and economic consequences.
The projects under the category of D&I demonstrate 
the potential for developing new technologies, result-
ing in the transfer of technology from universities to the 
production sector and interactions with the health eco-
nomic-industrial complex.
Results and discussion
There was a rapid reaction from Brazilian scientists; the 
search on the official websites of each of the 114 public 
universities, which are distributed throughout Brazil, 
retrieved information on 551 R&D projects, the majority 
of which originated in the Southeast region. As of May 
15, 2020, scientists had presented 270 research protocols 
related to COVID-19 to CONEP, including 46 clinical tri-
als and 224 observational studies, which were located in 
24 of the 27 states. Finally, the Ministry of Education’s 
official website reported approximately 73 proposals. In 
total, 894 initiatives were retrieved; after the elimina-
tion of duplicates, 789 RD&I projects were analyzed and 
are shown in the following tables/figures. The details are 
provided in Additional files 1 (Creation of Public Federal 
Universities and Public State Universities in Brazil, 1909–
2018), 2 (Federal investments in research and develop-
ment. Brazil 2000–2020) and 3 (Research, development 
& innovation about COVID-19 by institution, Brazil 
2020).
Table  1 presents the research projects, classified into 
categories as described before. With regard to the four 
broad categories, the majority of proposals (n = 280) 
were D&I projects that focused on PPE, medical devices, 
diagnostic tests, vaccines and medicines, which were rap-
idly identified as research priorities by the scientific com-
munity. These topics are extremely important under the 
current circumstances for the development of the health 
economic-industrial complex and the Brazilian capacity 
to attend to health needs [16].
The initiatives indicate a focus on translational health 
research [19] involving the transfer of knowledge gen-
erated in the basic sciences to the production of new 
products such as medicines, equipment, PPE, diagnos-
tic tests and innovative treatment options. These 280 
projects aim to bridge the gap between bench research 
and its application in health [19, 20].
The map of the Brazilian geographic regions in Fig. 1 
shows the distribution of research proposals developed 
by public universities, stratified by the project cat-
egories. Public universities from all Brazilian regions 
Table 1 Research, development and  innovation projects focusing on  COVID-19 led by  public universities and  public 
health research institutes
Brazil, 2020: Additional file with detailed descriptions available
Research category (number of projects per subcategory) Number Proportion (%)
Development and innovation (D&I) 280 35.6
Personal protective equipment (n = 45)
Medical devices (n = 36)
Diagnostic tests (n = 89)
Vaccines (n = 10)
Medications and therapy (n = 100)
Other types of COVID-19 research projects 226 28.6
Epidemiologic research 211 26.7
Basic research (focusing on disease mechanisms) 72 9.1
Total 789 100.0
Fig. 1 Regional distribution of research on COVID-19 in Brazil, May 
15, 2020
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were involved. The Southeast and Northeast regions 
accounted for 55.0% and 16.1% of the proposals, respec-
tively. The Central West, South and North regions 
accounted for 13.2%, 11.9% and 3.8%, respectively.
In terms of financial support, there was information 
on 140 projects that received funding, 116 of which were 
developed by federal universities and 24 led by state 
universities. The project category most likely to receive 
funds was D&I (25.7%), especially vaccine development 
(50.0%), as such projects present the health solutions 
most in line with the urgent needs of the healthcare 
system (Table 2). At the time of our data collection, the 
number of research proposals that had received funding 
was relatively low. This first analysis showed that despite 
inadequate funding, the Brazilian D&I sector offered sci-
entific and technological options capable of strengthen-
ing the health production chain in response to the public 
health emergency caused by the spread of COVID-19.
Out of the 789 research projects included and ana-
lyzed, there were only 10 vaccine projects (50% of which 
were financed). Considering the highly sophisticated 
laboratory facilities and clinical requirements for vac-
cine development, this is reasonable. However, there 
is evidence that the most promising vaccines for SUS 
and for the Brazilian population may come from two 
of these vaccine trials. One candidate vaccine based on 
the spike (S) glycoprotein is developed in partnership 
with Oxford University in the United Kingdom. The 
phase III study is under way and plans to enroll more 
than 30,000 volunteers worldwide. Brazil will participate 
in the tests, providing approximately 2000 volunteers 
under the supervision of the Federal University of São 
Paulo (UNIFESP) [10] and Fiocruz [21]. This partnership 
involves the production, by Fiocruz, of 100 million doses 
of the vaccine for the Brazilian population; 30 million 
doses could be available in December 2020/January 2021 
[21]. The other trial was of the CoronaVac vaccine, devel-
oped by the Chinese pharmaceutical company Sinovac 
Biotech, which involved 9000 volunteers in São Paulo, 
Brazil, in the final phase III trial. If proven effective and 
safe, national production will commence immediately 
due to technology transfer agreements with Butantan in 
São Paulo. The provision of doses to the SUS will be pos-
sible as early as June 2021 [22].
There are 211 projects classified as epidemiologic 
research, which include the development of several 
observatories, surveillance systems and mobile phone 
apps for COVID-19 monitoring at the local and national 
levels, especially for vulnerable populations. One exam-
ple is MONITORA COVID-19, developed by Fiocruz 
(https ://bigda ta-covid 19.icict .fiocr uz.br/), and another is 
the COVID-19 BR Observatory, established by the Fed-
eral University of ABC (https ://covid 19br.githu b.io/).
The COVID-19 health emergency is reminding all 
members of the scientific community of the reasons we 
embarked on research careers: we know that research is 
vital and valuable and can save lives. During this crisis, 
we are accelerating research production [23]. It is reas-
suring that society has come to recognize the fundamen-
tal role of solid scientific evidence [24].
Conclusions
Strong mobilization of the Brazilian scientific community 
took place in a very short time to respond to the COVID-
19 crisis, presenting 789 scientific proposals to address 
the most urgent problems posed by the pandemic. The 
interaction of universities, industries and governments 
is essential. In the absence of this linkage in Brazil, it is 
Table 2 Research, development and  innovation projects with  financial support focusing on  COVID-19 led by  public 
universities and public research institutes
Brazil, 2020: Additional file with detailed descriptions available
Research category (% of financed projects per subcategory) Number of projects Number of financed projects Proportion 
of financed 
projects (%)
Research, development and innovation 280 72 25.7
 Personal protective equipment (26.7%)
 Medical devices (38.9%)
 Diagnostic tests (15.7%)
 Vaccines (50.0%)
 Medications and therapy (27.9%)
Other types of COVID-19 research projects 226 13 5.8
Epidemiologic research 211 40 19.0
Basic research (focusing on disease mechanisms) 72 15 20.8
Total 789 140 17.7
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virtually impossible to perform translational research, 
that is, to take the results from the bench to the bedside, 
and from there to the healthcare system. It is necessary to 
enhance and encourage the interaction between univer-
sities and public research centers, which are involved in 
the production of scientific knowledge, and private com-
panies, which specialize in production on an industrial 
scale.
However, it must be emphasized that the rapid 
response observed in this survey was only possible due to 
decades of investment in the RD&I system in Brazil. We 
need to reinforce and protect this system from austerity 
policies that disregard health and knowledge as crucial 
investments for Brazilian society, in line with the con-
stitutional right to universal health access and universal 
health coverage.
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